NICE recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for treating obesity and controlling hunger caused by POMC or LEPR deficiency
BOSTON, USA, Monday 18th July, 2022 – Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the ...